ElectroCore, Inc. — Form 10-Q Summary
Business context and reporting period
ElectroCore is a commercial-stage medical device company developing and commercializing non-invasive vagus nerve stimulation therapy, primarily through its gammaCore products for migraine and cluster headache indications. The filing covers the three months ended March 31, 2021, compared with the three months ended March 31, 2020. The interim financial statements are unaudited.
Financial performance and position
| Metric | Q1 2021 | Q1 2020 | Change |
|---|---|---|---|
| Net sales | $1.204 million | $0.734 million | +64% |
| Gross profit | $0.840 million | $0.436 million | +$0.404 million |
| Gross margin | Approximately 70% | Approximately 59% | +11 percentage points |
| Operating expenses | $6.224 million | $8.449 million | -$2.225 million |
| Loss from operations | $(5.384) million | $(8.013) million | Loss narrowed by $2.630 million |
| Net loss | $(5.384) million | $(7.959) million | Loss narrowed by $2.576 million |
| Basic and diluted loss per share | $(0.11) | $(0.27) | Improved |
| Net cash used in operating activities | $(4.156) million | $(8.490) million | Cash use decreased by $4.335 million |
Revenue increased across the Commercial, U.S. Department of Veterans Affairs and Department of Defense, and United Kingdom channels. The VA/DoD and United Kingdom channels represented 81.3% of net sales, compared with 93.9% in the prior-year quarter. United States sales were $824 thousand, United Kingdom sales were $317 thousand, and other geographic sales were $63 thousand.
At March 31, 2021, cash and cash equivalents were $9.064 million and marketable securities were $16.388 million, for total cash, cash equivalents, and marketable securities of $25.453 million at fair value. Total assets were $33.750 million and total equity was $26.667 million.
Total debt consisted primarily of the Paycheck Protection Program loan, with $545.6 thousand classified as current and $863.8 thousand as noncurrent. The loan bears interest at 1.0% and matures February 2, 2023. The Company applied for forgiveness on March 24, 2021; no assurance was provided that any portion would be forgiven.
Material changes versus the prior comparable period
- Net sales rose 64%, driven by increased sales across all major channels.
- Gross margin improved to approximately 70% from 59%, primarily because of more favorable labor and overhead absorption and product mix.
- Research and development expense decreased 67% to $499 thousand, primarily reflecting reduced near-term investment and early termination of the Premium II clinical trial.
- Selling, general and administrative expense declined to $5.725 million from $6.561 million, reflecting cost-reduction measures and restructuring of the commercial channel.
- No restructuring or severance charges were recorded in Q1 2021, compared with $365 thousand in Q1 2020.
- Operating cash burn improved to $4.2 million from $8.5 million.
- The Company issued 2.75 million common shares under its Lincoln Park equity facility for approximately $6.9 million of proceeds and terminated that facility on March 11, 2021.
- Common shares outstanding increased to 48.493 million at March 31, 2021 from 45.560 million at December 31, 2020. An additional 165,413 shares were issued to settle certain executive accrued 2020 incentive bonuses.
Guidance, outlook, risks, contingencies, and unusual items
Management expects VA/DoD and United Kingdom revenue to remain a majority of revenue during the remainder of 2021. Management does not expect a material increase in selling, general and administrative expense during the rest of the year, although targeted commercial expenditures may continue. The filing does not provide quantitative revenue or earnings guidance.
The Company expects substantial negative operating cash flows and continued losses for at least the next several years while it seeks broader market acceptance of gammaCore. Management stated that existing capital resources are expected to fund operating expenses and capital requirements for at least the next 12 months, but also disclosed substantial doubt about the Company’s ability to continue as a going concern within one year because of recurring losses, negative cash flows, dependence on commercialization success, and the potential need for additional financing or significant reductions in activity.
COVID-19 continued to restrict access to prescribing physicians and headache patients, reducing the sales force’s ability to generate product interest. The Company stated that the pandemic adversely affected the reported quarter and that its longer-term impact remains uncertain. The gammaCore Sapphire CV emergency use authorization for acute treatment of asthma exacerbations in certain COVID-19 patients did not generate material revenue in the quarter, and the Company does not expect material revenue from that product.
Revenue is concentrated: VA/DoD accounted for 55.5% of Q1 2021 sales and the United Kingdom National Health Service accounted for 25.8%. Five VA/DoD facilities represented approximately 55.2% of VA/DoD revenue, with two facilities each accounting for more than 10% individually.
Shareholder securities and derivative litigation remains pending. The Company has not accrued a loss because it cannot determine the probability or range of potential loss. The matters could result in significant defense costs, settlements, or judgments. The filing also identifies foreign-currency exposure, dependence on third-party reimbursement and distribution channels, inventory-obsolescence risk, and the need for future funding.
Most important facts for investors to verify
- Whether revenue growth and improved gross margin are sustained after the quarter, particularly in the concentrated VA/DoD and U.K. channels.
- The rate of operating cash burn and whether approximately $25.5 million of cash and marketable securities will support operations beyond the stated 12-month period.
- Whether additional equity or debt financing will be required and the resulting dilution or financing terms.
- The status and outcome of the $1.4 million PPP loan forgiveness application.
- The continuing impact of COVID-19 on physician access, patient demand, supply chains, and commercialization activities.
- The status and potential financial exposure of the pending securities and derivative litigation.
- Whether the Company’s adolescent migraine clearance, international distributors, telemedicine, and cash-pay initiatives produce material incremental revenue.